TY - JOUR
T1 - Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents
AU - Bligaard, Niels
AU - Thuesen, Leif
AU - Saunamäki, Kari
AU - Thayssen, Per
AU - Aarøe, Jens
AU - Hansen, Peter Riis
AU - Lassen, Jens Flensted
AU - Stephansen, Ghita
AU - Jeppesen, Jørgen L
AU - Galløe, Anders Michael
AU - SORT OUT II investigators
N1 - Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents
June 2014, Vol. 48, No. 3 , Pages 148-155 (doi:10.3109/14017431.2014.883461)
HTML
PDF (158 KB)
PDF Plus (173 KB)
Reprints
Permissions
Niels Bligaard, Leif Thuesen, Kari Saunamäki, Per Thayssen, Jens Aarøe, Peter Riis Hansen, Jens Flensted Lassen, Ghita Stephansen, Jørgen L. Jeppesen, Anders Michael Galløe, and
1Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
2Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark
3Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
4Department of Cardiology, Odense University Hospital, Odense, Denmark
5Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
6Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
7Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark
Correspondence: Anders Michael Galløe, Department of Cardiology, Roskilde University Hospital, K gevej 7-13, DK-4000 Roskilde, Denmark. Tel: + 45-40-45-24-29. Fax: + 45-46-36-27-97. E-mail: [email protected]
Read More: http://informahealthcare.com/doi/abs/10.3109/14017431.2014.883461
PY - 2014/6
Y1 - 2014/6
N2 - OBJECTIVE: Millions of patients were treated with the sirolimus-eluting Cypher™ and the paclitaxel-eluting Taxus™ coronary stents with potential late-occurring increase in event rates. Therefore, the long-term outcome follow-up is of major clinical interest.DESIGN: In total, 2.098 unselected patients with ST-segment elevation myocardial infarction (STEMI), non-STEMI, stable or unstable angina pectoris were randomized to receive Cypher™ (n = 1.065) or Taxus™ (n = 1.033) stents and were followed for 5 years.RESULTS: The primary end-point; the composite of cardiac death, myocardial infarction and target vessel revascularization (major adverse cardiac event, MACE), occurred in 467 patients (22.3%); Cypher™ n = 222 (20.8%), Taxus™ n = 245 (23.7%), ns. Definite and probable stent thrombosis occurred in 107 patients (5.1%); Cypher™ n = 51 (4.8%), Taxus™ n = 56 (5.4%), ns. No statistically significant differences were found in the elements of the primary end-point or in other secondary end-points between the two stent groups. After one year, the annual rates of stent thrombosis and MACE remained constant.CONCLUSIONS: During 5-year follow-up, the Cypher™ and the Taxus™ coronary stents had similar clinical outcome with no signs of increasing rates of adverse events over time.
AB - OBJECTIVE: Millions of patients were treated with the sirolimus-eluting Cypher™ and the paclitaxel-eluting Taxus™ coronary stents with potential late-occurring increase in event rates. Therefore, the long-term outcome follow-up is of major clinical interest.DESIGN: In total, 2.098 unselected patients with ST-segment elevation myocardial infarction (STEMI), non-STEMI, stable or unstable angina pectoris were randomized to receive Cypher™ (n = 1.065) or Taxus™ (n = 1.033) stents and were followed for 5 years.RESULTS: The primary end-point; the composite of cardiac death, myocardial infarction and target vessel revascularization (major adverse cardiac event, MACE), occurred in 467 patients (22.3%); Cypher™ n = 222 (20.8%), Taxus™ n = 245 (23.7%), ns. Definite and probable stent thrombosis occurred in 107 patients (5.1%); Cypher™ n = 51 (4.8%), Taxus™ n = 56 (5.4%), ns. No statistically significant differences were found in the elements of the primary end-point or in other secondary end-points between the two stent groups. After one year, the annual rates of stent thrombosis and MACE remained constant.CONCLUSIONS: During 5-year follow-up, the Cypher™ and the Taxus™ coronary stents had similar clinical outcome with no signs of increasing rates of adverse events over time.
U2 - 10.3109/14017431.2014.883461
DO - 10.3109/14017431.2014.883461
M3 - Journal article
C2 - 24548278
SN - 1401-7431
VL - 48
SP - 148
EP - 155
JO - Scandinavian cardiovascular journal : SCJ
JF - Scandinavian cardiovascular journal : SCJ
IS - 3
ER -